United States - English - NLM (National Library of Medicine)

sandoz inc - pioglitazone hydrochloride (unii: jqt35npk6c) (pioglitazone - unii:x4ov71u42s), glimepiride (unii: 6ky687524k) (glimepiride - unii:6ky687524k) - pioglitazone 30 mg - pioglitazone and glimepiride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are already treated with a thiazolidinedione and sulfonylurea or who have inadequate glycemic control on a thiazolidinedione alone or a sulfonylurea alone [see clinical studies (14)]. important limitations of use pioglitazone exerts its antihyperglycemic effect only in the presence of endogenous insulin. pioglitazone and glimepiride tablets should not be used to treat type 1 diabetes or diabetic ketoacidosis, as it would not be effective in these settings. use caution in patients with liver disease [see warnings and precautions (5.5)]. reported hypersensitivity reactions with glimepiride include cutaneous eruptions with or without pruritus as well as more serious reactions (e.g., anaphylaxis, angioedema, stevens-johnson syndrome, dyspnea) [see warnings and precautions (5.3) and adverse reactions (6.2)] risk summary limited data with pioglitazone and

United States - English - NLM (National Library of Medicine)

prasco laboratories - pioglitazone hydrochloride (unii: jqt35npk6c) (pioglitazone - unii:x4ov71u42s), glimepiride (unii: 6ky687524k) (glimepiride - unii:6ky687524k) - pioglitazone 30 mg - pioglitazone and glimepiride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are already treated with a thiazolidinedione and sulfonylurea or who have inadequate glycemic control on a thiazolidinedione alone or a sulfonylurea alone [see clinical studies (14)] . important limitations of use pioglitazone exerts its antihyperglycemic effect only in the presence of endogenous insulin. pioglitazone and glimepiride tablets should not be used to treat type 1 diabetes or diabetic ketoacidosis, as it would not be effective in these settings. use caution in patients with liver disease [see warnings and precautions (5.5)]. - initiation in patients with established nyha class iii or iv heart failure [see boxed warning] . - use in patients with known hypersensitivity to pioglitazone, glimepiride or any other component of pioglitazone and glimepiride tablets [see warnings and precautions (5.3)] . - use in patients with known history of an alle

United States - English - NLM (National Library of Medicine)

takeda pharmaceuticals america, inc. - pioglitazone hydrochloride (unii: jqt35npk6c) (pioglitazone - unii:x4ov71u42s), glimepiride (unii: 6ky687524k) (glimepiride - unii:6ky687524k) - pioglitazone 30 mg - duetact is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are already treated with a thiazolidinedione and sulfonylurea or who have inadequate glycemic control on a thiazolidinedione alone or a sulfonylurea alone [see clinical studies (14)] . important limitations of use pioglitazone exerts its antihyperglycemic effect only in the presence of endogenous insulin. duetact should not be used to treat type 1 diabetes or diabetic ketoacidosis, as it would not be effective in these settings. use caution in patients with liver disease [see warnings and precautions (5.5)] . reported hypersensitivity reactions with glimepiride include cutaneous eruptions with or without pruritus as well as more serious reactions (e.g., anaphylaxis, angioedema, stevens-johnson syndrome, dyspnea) [see warnings and precautions ( 5.3) and adverse reactions (6.2)] risk summary limited data with duetact or pioglitazone in pregnant women are not sufficient to determine a d

European Union - English - EMA (European Medicines Agency)

cheplapharm arzneimittel gmbh - pioglitazone, glimepiride - diabetes mellitus, type 2 - drugs used in diabetes - tandemact is indicated for the treatment of patients with type-2 diabetes mellitus who show intolerance to metformin or for whom metformin is contraindicated and who are already treated with a combination of pioglitazone and glimepiride.

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

الشركة العربية لصناعة الادوية المساهمة الخاصة - the arab pharmaceutical manufacturing psc - pioglitazone (as pioglitazone hcl) 30 mg, glimepiride 2 mg - (as pioglitazone hcl) 30 mg, 2 mg

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

الشركة العربية لصناعة الادوية المساهمة الخاصة - the arab pharmaceutical manufacturing psc - pioglitazone (as pioglitazone hcl) 30 mg, glimepiride 2 mg - (as pioglitazone hcl) 30 mg, 2 mg

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

الشركة العربية لصناعة الادوية المساهمة الخاصة - the arab pharmaceutical manufacturing psc - pioglitazone (as pioglitazone hcl) 30 mg, glimepiride 4 mg - (as pioglitazone hcl) 30 mg, 4 mg

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

الشركة العربية لصناعة الادوية المساهمة الخاصة - the arab pharmaceutical manufacturing psc - pioglitazone (as pioglitazone hcl) 30 mg, glimepiride 4 mg - (as pioglitazone hcl) 30 mg, 4 mg

Philippines - English - FDA (Food And Drug Administration)

n/a; importer: getz pharma (phils.) inc.; distributor: n/a - pioglitazone (as hydrochloride) , glimepiride - tablet - 15mg/2mg - anti-diabetic - as an adjunct to diet and exercise for the improvement of glycemic control in patients with type 2 diabetes mellitus who are already treated with pioglitazone and a sulfonylurea and whose diabetes is not adequately controlled with glimepiride alone or those patients who have initially responded to pioglitazone alone and require additional glycemic control.

Philippines - English - FDA (Food And Drug Administration)

getz pharma., phils., inc. - pioglitazone (as hydrochloride) , glimepiride - tablet - 30mg/2mg - anti-diabetic - as an adjunct to diet and exercise for the improvement of glycemic control in patients with type 2 diabetes mellitus who are already treated with pioglitazone and a sulfonylurea and whose diabetes is not adequately controlled with glimepiride alone or those patients who have initially responded to pioglitazone alone and require additional glycemic control.